Innovimmune Biotherapeutics Holding

Innovimmune Biotherapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel first-in-class small molecule immunotherapies. The company leverages its proprietary discovery platform to target key pathways in inflammation, autoimmunity, and oncology, with a particular emphasis on the Macrophage Migration Inhibitory Factor (MIF) cytokine family. Their lead programs include dual MIF/DDT inhibitors and ROR-gamma inverse agonists designed to treat complex immune-mediated diseases such as rheumatoid arthritis and multiple sclerosis. Innovimmune aims to provide oral, non-biologic alternatives to current injectable therapies for chronic inflammatory conditions.